Promising phase II biologics for future Crohn’s disease therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Promising phase II biologics for future Crohn’s disease therapy

Published:2023-05-31 Issue:6 Volume:32 Page:495-507
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Wils Pauline¹²,Danese Silvio³^ORCID,Peyrin-Biroulet Laurent⁴⁵

Affiliation:

1. Department of Gastroenterology, Claude Huriez Hospital, University of Lille 2, Lille, France

2. Inserm, CHU Lille, U1286- INFINITE- Institute for Translational Research in Inflammation, University of Lille, Lille, France

3. Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy

4. CHRU-Nancy, Department of Gastroenterology,University of Lorraine, Nancy, France

5. Inserm, University of Lorraine, Nancy, France

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2023.2219386

Reference70 articles.

1. Crohn's disease

2. The Natural History of Adult Crohn's Disease in Population-Based Cohorts

3. Pathophysiology of Inflammatory Bowel Diseases

4. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

5. Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibrosis in IBD: from pathogenesis to therapeutic targets;Gut;2024-01-17

2. The Current Status and Prospects of the Application of Mirikizumab in Inflammatory Bowel Disease;Advances in Clinical Medicine;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3